Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.5.52NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.65NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.75NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.21NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.18.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.24NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GL.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.24NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.78NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.45NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
K.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.56NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.41NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KF.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
ANUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.1.48.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BN.1.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BU.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EW.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BE.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BW.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FB.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-15983.3US
BF.7.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DN.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.28NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CJ.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBF.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BQ.1.1.31NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.3.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HH.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.22.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GY.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HW.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.38NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used